BIOAFFINITY TECHNOLOGIES INC (BIAF)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$2.97-6.90%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · BIAF
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -78.7% |
| Our one-year growth estimate | diamond | 5.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 84.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 13 industry peers
BIAF — private placement
Dated 2026-10-09
Entry into a Material Definitive Agreement. On October 8, 2026, bioAffinity Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor: (i) 116,545 shares (the “Shares”) of common stock of the Company (the “Common Stock”), and (ii) pre-funded warrants to purchase up to an aggregate of 536,836 shares of Common Stock (the “Pre-Funded Warrants”).…
Why it matters: The study can add evidence on how the test performs. Enrollment began at 11 sites, including nine VA and military centers.
Supportive ifA company update says enrollment is above the starting level of 11 sites. It also shares study results that support the test's performance.
Worry ifThe company says enrollment has stalled, sites have left, or study results do not back the test's performance.
Why it matters: Sales more than doubled through Q3. Another year-over-year gain above 100% would show that growth continues as the customer base grows.
Supportive ifThe next results show CyPath Lung sales or test volume up more than 100% year over year in Q4.
Worry ifThe next results show CyPath Lung sales or test volume up less than 50% year over year, or down year over year.
Why it matters: More repeat orders would show that clinics keep using the test after trying it. That helps test whether sales growth reaches existing customers.
Supportive ifThe next update shows test volume from clinics that ordered by Q3 2025 up at least 48% year over year.
Worry ifThe next update shows test volume from those clinics flat or lower year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$476 on $10,000 · ±4.8% | How much price usually moves either way. |
| Bad day | $1,663 loss on $10,000 · 16.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,606 loss on $10,000 · 96.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.